ReviewHerzschrittmachertherapie & Elektrophysiologie2026
Value of the 12-lead ECG to localize the origin of ventricular tachycardia.
Review in Herzschrittmachertherapie & Elektrophysiologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 12-lead electrocardiogram (ECG) recorded during ventricular tachycardia (VT) remains a simple, universally available tool for VT localization. In idiopathic VT, QRS morphology and polarity often reflect the site of earliest activation and can facilitate targeted mapping. In patients with structural heart disease, however, the surface ECG predominantly represents the VT exit region rather than the critical diastolic isthmus; thus, its main clinical value lies in regionalization and in planning ablation strategy and access. A pragmatic stepwise interpretation integrating V1 morphology, precordial transition (V1-V6), and the frontal plane axis can localize VT in most cases, although accuracy is influenced by scar size, conduction abnormalities, antiarrhythmics, and variable exit sites. Emphasis is placed on estimating epicardial or intramural involvement using interval- and morphology-based criteria-especially in nonischemic cardiomyopathy-and on integrating ECG findings with cardiac scar imaging. Key disease-specific ECG patterns are highlighted. Electrocardiographic imaging, automated ECG analysis, and artificial intelligence (AI)-based localization approaches may further improve VT localization.
Indexed as
Identifiers
42573615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.